DelMar Pharmaceuticals Inc. announced that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP).The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and the B.C. Cancer Agency. This funding represents the fourth contribution that DelMar has received from NRC-IRAP, bringing the total to CDN$327,000 in financial support to date.
“We are pleased to receive advisory services and technological expertise along with funding support from NRC-IRAP and appreciate Canada’s ongoing commitment to support growing companies like DelMar Pharmaceuticals,” said Jeffrey Bacha, president & CEO. “This funding will support personnel and research costs and enable us to accelerate and broaden non-clinical research aimed at further establishing the competitive differentiation of our lead product candidate, VAL-083, as a potential chemotherapy for the treatment of glioblastoma multiforme and non-small cell lung cancer.”
Date: July 9, 2014
Source: DelMar Pharmaceuticals
Filed Under: Drug Discovery
